- In the STEP 1 trial extension, participants who stopped weekly semaglutide and lifestyle support regained about two thirds of their lost weight within a year. Those results come from the branded, FDA-approved product, not compounded preparations.
- Regain is physiology, not weakness. The medication changes appetite signals; stopping restores them, and the body defends its old setpoint.
- Not everything reverses. Habits built, strength gained through training, and what you learned about your own eating stay yours.
- There are good reasons to stop: pregnancy plans, side effects, cost, reached goals. Do it with your clinician, on a plan, rather than cold turkey.
- The more useful frame is ongoing care, like blood pressure treatment, rather than a course of antibiotics with a finish line.
What the evidence shows
Start with the best data available, because it is unusually clean. STEP 1 was a large randomized trial of weekly semaglutide for weight: 1,961 adults, 68 weeks of treatment alongside lifestyle support, run with the branded, FDA-approved product rather than compounded preparations. Participants on semaglutide lost an average of 17.3% of their body weight; the placebo group lost 2.0%. Then, at week 68, everything stopped, the medication and the lifestyle program both, and researchers followed a subset of 327 participants for a full year off treatment.
A year later, the semaglutide group had regained an average of 11.6 percentage points of the 17.3% they had lost, roughly two thirds of it, leaving them a net 5.6% below their starting weight at week 120. The improvements in blood pressure, blood lipids, and other cardiometabolic measures largely retraced their steps toward baseline along with the weight. The authors' own conclusion is the one worth memorizing: the findings confirm the chronicity of obesity and suggest that ongoing treatment is required to maintain the improvements.
Read that fairly, in both directions. Two thirds regained means the medication was doing real work the entire time, and that the work does not survive its absence. It also means one third of the loss, on average, had not returned at the one-year mark, and that participants remained measurably below where they started. The picture is not “stopping erases everything.” It is “stopping starts a slide, and the slide is substantial.” One honest caveat cuts the other way: the trial withdrew the lifestyle support along with the medication, so someone who keeps their habits after stopping is in slightly better shape than the trial average, a point we will return to.
Why the weight comes back
The regain has a mechanism, and knowing it changes how the whole subject feels. GLP-1 medications work by supplying a signal: they act on the receptors that tell your brain you are fed, quiet the reward-driven chatter around food, and slow the stomach so meals last. While the medication is present, your appetite is running on that borrowed signal. Stop the medication, and within weeks the signal is gone. Nothing is broken. The system has simply returned to its factory settings, and the factory settings are the ones that built the original weight.
Appetite comes back first, and members who stop describe it less as hunger than as noise: the background negotiation with food, the mental real estate, the pull of the pantry at 9pm. We wrote a whole piece on food noise and the hormone that quiets it, and stopping treatment is, mechanically, the volume knob turning back up.
Underneath that sits something older. A body that has carried a higher weight for years treats that weight as the level to defend. Lose weight by any method, diet, surgery, or medication, and the body responds with a countercampaign: hunger hormones rise, fullness hormones fall, and energy expenditure drifts down, all pushing back toward the old setpoint. This is why regain after any weight loss is the norm rather than the exception, and why it is worth saying plainly: regaining weight after stopping a GLP-1 is not a failure of character. It is physiology doing exactly what physiology does. The medication was holding a door against a spring. Let go of the door and the spring is still there.
What does not vanish
Honesty about regain should not curdle into fatalism, because the trial average is not a prophecy, and several things you build during treatment are genuinely yours to keep.
Habits survive. Months of eating protein first, of smaller portions, of water as a discipline, of reading your own fullness signals, those patterns were learned by you, not lent by the medication. The trial participants lost their lifestyle program at the same moment they lost the medication; you do not have to. Kept habits will not fully hold the line against returning appetite, and pretending otherwise would be dishonest, but they are the difference between the slide and the cliff.
Strength stays with whoever trains. Muscle built through resistance training during treatment does not evaporate when a prescription ends; it responds to training, not to semaglutide. Members who followed something like a real strength protocol and kept protein on the plate step off treatment with a better body composition and a higher-functioning metabolism than they brought to it.
Knowledge does not regress. You now know how your body responds to treatment, what your appetite feels like with the noise off, which foods serve you, and what your numbers did. That information keeps paying whether or not you resume. On the health markers themselves, the honest report from the extension data is mixed: most cardiometabolic improvements tracked the weight back up. What you keep there is not the numbers; it is the proof of what the numbers can be.
Legitimate reasons to stop
A page like this could easily read as an argument that no one should ever stop. That is not the position, and it is not true. Clinicians take members off GLP-1s for good reasons, regularly.
Planning a pregnancy. This one is not optional: GLP-1 medications are stopped before trying to conceive, on a timeline your clinician will set. The full picture, including the planning windows, is in our pregnancy article, and it is the clearest case of a stop that is simply the right call.
Side effects that will not settle. Most side effects ease with time and dose adjustment, but not all, and a treatment that makes life worse than the problem it treats has failed on its own terms. Sometimes the answer is a different dose, sometimes a different medication, sometimes a stop.
Cost. Treatment has a price, and pretending budgets do not exist helps no one. If cost is the pressure, say so before stopping outright: longer plans lower the monthly price, and the cash-pay math is worth running with real numbers before deciding the answer is zero.
Reaching your goal. Some members arrive at goal weight and reasonably want to try holding it without help. That is a legitimate experiment, and the evidence above says to run it with open eyes, a plan for the returning appetite, and a low threshold for resuming if the slide starts.
“The medication did not fail when the weight returned. It was working the whole time. Stopping is when it stops working, which is true of every treatment for every chronic condition we manage.”
Dr. Priya Shah, MD
How to stop well
However you arrive at the decision, the exit deserves the same clinical care as the entrance. Cold turkey, the canceled subscription and the vial that simply runs out, is the worst available version: appetite returns on its own schedule, nothing is watching the scale, and the first anyone hears of it is a regain already in motion.
Stopping well looks different. It starts as a conversation with your clinician about why, because the reason shapes the plan: a pregnancy timeline is not a budget problem is not a side-effect problem. It often includes a taper rather than a hard stop, stepping the dose down the same ladder it climbed, which gives your appetite a gradient instead of a wall; the logic of that ladder is the same one covered in our titration guide, run in reverse. It sets up the off-ramp months on purpose: protein and strength work locked in, weigh-ins at an honest cadence, and an agreed threshold at which you and your clinician revisit the decision rather than watching the slide continue out of pride.
And for a growing number of members, the conversation lands somewhere between all and nothing: a maintenance dose. Holding weight is a different job than losing it, and it often takes less medication; some members stay at a lower dose long term rather than stopping outright. That option has its own article, our guide to maintenance, and it is frequently the answer to “I want to stop” that actually addresses what the member wants, which is to stop escalating, not to lose the ground they gained.
Treatment, not a course
Here is the reframe the evidence keeps pointing at. Most of us were raised on the antibiotics model of medication: take the course, finish the course, be done. GLP-1 treatment does not work that way, because obesity does not work that way. The trial authors called it chronicity; in practice it means the condition persists and the treatment manages it, the way blood pressure medication manages hypertension. Nobody finishes blood pressure treatment, and when pressure rises after stopping, nobody calls the medication a failure or the person weak. We simply understand the medication was doing its job, and the job is ongoing.
Held to that standard, the STEP extension data stops being an indictment and becomes a description: this is what managing a chronic condition looks like when management pauses. The question “how long will I be on this?” gets an honest answer, which is: as long as it is doing work you value, at the lowest dose that does it, reviewed by a clinician at a regular rhythm, exactly like the other conditions medicine manages for the long haul. Some members will stop anyway, for the good reasons above, and that is fine. The frame is not a trap. It is just the truth about what kind of undertaking this is, offered before you start rather than discovered at week 69.
Where quarterly plans fit
If treatment is ongoing care, the structure around it should be built for years, not months, and this is where Parke's quarterly rhythm earns its place. Members on quarterly plans receive three months of medication per shipment, at a lower average monthly price than month-to-month, with a provider medical check-in each quarter: a clinician reviewing your weight trend, side effects, dose, and goals, and adjusting the plan while changes are still small. That cadence is the practical opposite of the cold-turkey exit. Dose changes, maintenance conversations, and even a well-planned stop all have a natural place to happen, because someone with your chart in front of them is already scheduled to ask how it is going.
The fuller case is in the quiet case for quarterly refills. For this article, the point is narrower: the biggest risk in GLP-1 treatment is not starting it. It is drifting out of it, unsupervised, and meeting your old appetite alone. Structure is how you do not drift.
Endocrinologist at Parke, focused on metabolic health and the hormonal systems that govern appetite and weight. She reviewed the trial characterizations and clinical claims in this article. Nothing here replaces the judgment of the clinician who knows your chart.
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022. Full text via PubMed Central.
This article is general information, not medical advice, and trial results describe group averages, not any individual's outcome. The cited findings come from branded, FDA-approved semaglutide under clinical trial conditions, not from compounded preparations. Decisions about starting, changing, or stopping treatment belong with a licensed clinician who knows your health history. Compounded medications are prepared by state-licensed US compounding pharmacies and are not FDA-approved or evaluated. Review the important safety information on each treatment page.
